129 related articles for article (PubMed ID: 30199786)
1. Anti-c-Mpl antibodies in immune thrombocytopenia suppress thrombopoiesis and decrease response to rhTPO.
Jing FM; Zhang XL; Meng FL; Liu XM; Shi Y; Qin P; Wang L; Zhou H; Hou Y; Song Q; Peng J; Hou M
Thromb Res; 2018 Oct; 170():200-206. PubMed ID: 30199786
[TBL] [Abstract][Full Text] [Related]
2. Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia.
Kuwana M; Okazaki Y; Kajihara M; Kaburaki J; Miyazaki H; Kawakami Y; Ikeda Y
Arthritis Rheum; 2002 Aug; 46(8):2148-59. PubMed ID: 12209520
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia.
Shin J; Kim MJ; Quan X; Kim JW; Lee S; Park S; Jeong JY; Yea K
BMC Cancer; 2023 May; 23(1):490. PubMed ID: 37259024
[TBL] [Abstract][Full Text] [Related]
4. Romiplostim: a second-generation thrombopoietin agonist.
Cohn CS; Bussel JB
Drugs Today (Barc); 2009 Mar; 45(3):175-88. PubMed ID: 19436840
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia.
Wang X; Bi H; Liu L; Liu Y; Yin L; Yao J; Yu J; Tao W; Wei Y; Li Y; Yin L; Mu H; Du Y; Zhou Z
Platelets; 2023 Dec; 34(1):2271568. PubMed ID: 37941414
[TBL] [Abstract][Full Text] [Related]
6. [Role of anti c-mpl antibody in systemic lupus erythematosus with thrombocytopenia].
Yang T; Huang CB; Lai B; Zhao LK; Chen YJ; Zhao YT; Zhang CM; Zeng XF
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 44(2):221-4. PubMed ID: 22516991
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between the expression of autoantibodies against platelet membrane glycoprotein and therapeutic effect in primary immune thrombocytopenia].
Liu XF; Xue F; Zhang L; Zhou XL; Liu YZ; Liu W; Chen YF; Huang YT; Yang RC
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):610-3. PubMed ID: 23906456
[TBL] [Abstract][Full Text] [Related]
8. Cloning of thrombopoietin and its therapeutic potential.
Miyazaki H
Cancer Chemother Pharmacol; 1996; 38 Suppl():S74-7. PubMed ID: 8765422
[TBL] [Abstract][Full Text] [Related]
9. Effect of recombinant human thrombopoietin on immune thrombocytopenia in pregnancy in a murine model.
Liu Y; Wang R; Han P; Zhao Y; Li G; Li G; Nie M; Wang L; Chen J; Liu X; Hou M
Int Immunopharmacol; 2019 Feb; 67():287-293. PubMed ID: 30572253
[TBL] [Abstract][Full Text] [Related]
10. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
Makar RS; Zhukov OS; Sahud MA; Kuter DJ
Am J Hematol; 2013 Dec; 88(12):1041-4. PubMed ID: 23913253
[TBL] [Abstract][Full Text] [Related]
11. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura.
Gernsheimer TB
Hematology Am Soc Hematol Educ Program; 2008; ():219-26. PubMed ID: 19074086
[TBL] [Abstract][Full Text] [Related]
12. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia.
Wang S; Yang R; Zou P; Hou M; Wu D; Shen Z; Lu X; Li Y; Chen X; Niu T; Sun H; Yu L; Wang Z; Zhang Y; Chang N; Zhang G; Zhao Y
Int J Hematol; 2012 Aug; 96(2):222-8. PubMed ID: 22753022
[TBL] [Abstract][Full Text] [Related]
13. Targeting a thrombopoietin-independent strategy in the discovery of a novel inducer of megakaryocytopoiesis, DMAG, for the treatment of thrombocytopenia.
Wang L; Liu S; Luo J; Mo Q; Ran M; Zhang T; Li X; Zou W; Mei Q; Chen J; Yang J; Zeng J; Huang F; Wu A; Zhang C; Wu J
Haematologica; 2023 May; 108(5):1394-1411. PubMed ID: 36546424
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin and its receptor expression in pediatric patients with chronic immune thrombocytopenia.
Li S; Shao J; Xia M; Zhang N; Yang J; Li H; Jiang H
Hematology; 2018 Aug; 23(7):433-438. PubMed ID: 29313460
[TBL] [Abstract][Full Text] [Related]
15. Response loss and development of neutralizing antibodies during long-term treatment with romiplostim in patients with immune thrombocytopenia: a case series.
Carpenedo M; Cantoni S; Coccini V; Pogliani EM; Cairoli R
Eur J Haematol; 2016 Jul; 97(1):101-103. PubMed ID: 26718013
[TBL] [Abstract][Full Text] [Related]
16. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
[TBL] [Abstract][Full Text] [Related]
17. Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count.
Lev PR; Grodzielski M; Goette NP; Glembotsky AC; Espasandin YR; Pierdominici MS; Contrufo G; Montero VS; Ferrari L; Molinas FC; Heller PG; Marta RF
Br J Haematol; 2014 Jun; 165(6):854-64. PubMed ID: 24673454
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin factors.
Wei P
Cancer Treat Res; 2011; 157():75-93. PubMed ID: 21052951
[TBL] [Abstract][Full Text] [Related]
19. [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia].
Bai CM; Zou XY; Zhao YQ; Han SM; Shan YD;
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):397-400. PubMed ID: 15061993
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: a prospective study.
Wu Q; Ren J; Wu X; Wang G; Gu G; Liu S; Wu Y; Hu D; Zhao Y; Li J
J Crit Care; 2014 Jun; 29(3):362-6. PubMed ID: 24405656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
